Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
loncastuximab tesirine + glofitamab
- Development stage
- Unknown
- Lead developer
- ADC Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Loncastuximab tesirine + glofitamab** is a combination therapy under investigation for treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Loncastuximab tesirine is an antibody-drug conjugate (ADC) targeting CD19, a B-cell antigen, with a humanized monoclonal IgG1 antibody conjugated to the cytotoxic SG3199 pyrrolobenzodiazepine (PBD) dimer via a protease-cleavable linker. It binds CD19, is internalized, and releases its cytotoxin to induce DNA crosslinks and cell death. Glofitamab is a bispecific monoclonal antibody that simultaneously binds CD20 on B cells and CD3 on T cells, recruiting and activating T cells for B-cell lysis. The combination leverages two distinct mechanisms—targeted cytotoxicity and immune-mediated killing—for potential synergy in aggressive B-cell lymphomas[1][2][3][5].
- Brand names
- ZYNLONTAColumvi
- Other names
- loncastuximab tesirine + glofitamab
02
Targets
CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)DNA minor groove
Beyond the preview
Go deeper on loncastuximab tesirine + glofitamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on loncastuximab tesirine + glofitamab.